<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01177657</url>
  </required_header>
  <id_info>
    <org_study_id>111562</org_study_id>
    <nct_id>NCT01177657</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effectiveness of Rotarix™ Against Severe Gastroenteritis Among Hospitalized Children in Brazil</brief_title>
  <official_title>Case-control Study to Evaluate the Vaccine Effectiveness of Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) Among Hospitalized Children Born After 6 March 2006 and at Least 12 Weeks of Age, in Belem, Brazil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate the effectiveness of 2 doses of Rotarix™ vaccination&#xD;
      in preventing rotavirus severe gastroenteritis among children hospitalized in Belem area,&#xD;
      Brazil.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be comprised of two parts: Case-control study and Rotavirus strain&#xD;
      surveillance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Risk of Enzyme Linked Immunosorbent Assay (ELISA) confirmed rotavirus severe gastroenteritis in children fully vaccinated with Rotarix™, compared to risk of ELISA confirmed rotavirus severe gastroenteritis in unvaccinated children</measure>
    <time_frame>Average time frame: 12-24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk of ELISA confirmed rotavirus severe gastroenteritis in children vaccinated with at least one dose of Rotarix™, compared to risk of ELISA confirmed rotavirus severe gastroenteritis in unvaccinated children</measure>
    <time_frame>Average time frame: 12-24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of severe gastroenteritis among children admitted to study clinics/hospitals for severe gastroenteritis</measure>
    <time_frame>Average time frame: 12-24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of rotavirus serotypes among children</measure>
    <time_frame>Average time frame: 36 months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">1944</enrollment>
  <condition>Rotavirus Gastroenteritis</condition>
  <arm_group>
    <arm_group_label>Gastroenteritis cohort</arm_group_label>
    <description>Children born after 6 March 2006, at least 12 weeks of age and hospitalized for rotavirus severe gastroenteritis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hospital control cohort</arm_group_label>
    <description>Children hospitalized for non gastroenteritis causes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neighbourhood control cohort</arm_group_label>
    <description>Children without any symptoms of gastroenteritis or severe gastroenteritis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stool sampling</intervention_name>
    <description>Stool samples collected and checked for the presence of rotavirus</description>
    <arm_group_label>Gastroenteritis cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Gastroenteritis Cohort: Cases will include children born after 6 March 2006, at least 12&#xD;
        weeks of age and hospitalized for rotavirus severe gastroenteritis the study&#xD;
        clinics/hospitals, during the designated study period, Hospital control cohort: Children&#xD;
        hospitalized for non gastroenteritis causes, Neighbourhood control cohort: Children without&#xD;
        any symptoms of gastroenteritis or severe gastroenteritis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For cases:&#xD;
&#xD;
          -  A male or female child born after 6 March 2006 and at least 12 weeks of age.&#xD;
&#xD;
          -  Subject admitted to the study clinics/hospitals for severe gastroenteritis during the&#xD;
             study period.&#xD;
&#xD;
          -  Onset of severe gastroenteritis ≤ 14 days prior to admission.&#xD;
&#xD;
          -  Laboratory confirmed rotavirus positive stool sample at hospital admission or during&#xD;
             the first 48 hours of hospitalization.&#xD;
&#xD;
          -  Written informed consent obtained from the parent or guardian of the subject.&#xD;
&#xD;
        For controls:&#xD;
&#xD;
          -  Admitted for non-gastroenteritis causes at the same clinic/hospital as the case.&#xD;
&#xD;
          -  Living in the same neighbourhood as the case for at least three consecutive months&#xD;
             without any symptoms of gastroenteritis or severe gastroenteritis on the day of&#xD;
             interview of his/ her parents/ guardians.&#xD;
&#xD;
          -  Being born within +- 2 weeks from the date of birth of the case. If the number&#xD;
             required is not available, then the range would be extended to +- 4 weeks, and&#xD;
             ultimately up to +- 6 weeks for hospital controls. For neighbourhood controls, the&#xD;
             range may be extended to +- 8 weeks.&#xD;
&#xD;
          -  Written informed consent obtained from the parent or guardian of the child.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For cases:&#xD;
&#xD;
          -  Subject has previously participated as case or control in this study.&#xD;
&#xD;
          -  Onset of severe gastroenteritis &gt; 48 hours after admission to the hospital (nosocomial&#xD;
             infections).&#xD;
&#xD;
        For controls:&#xD;
&#xD;
          -  For hospital controls: Child who has symptoms of gastroenteritis during current&#xD;
             hospitalization or on the day of interview of his/her parent or guardian or for&#xD;
             neighbourhood controls: Child who has symptoms of gastroenteritis or severe&#xD;
             gastroenteritis on the day of interview of his/her parent or guardian.&#xD;
&#xD;
          -  Exclude children with the following vaccine preventable diseases: measles, mumps,&#xD;
             rubella, diphtheria, pertussis, tetanus, tuberculosis, invasive Haemophilus influenzae&#xD;
             type B (Hib) infections (meningitis, bacteraemia, septic arthritis, cellulitis, and&#xD;
             epiglottitis) and hepatitis B.&#xD;
&#xD;
          -  Child has participated in the past as a case or control in this study.&#xD;
&#xD;
          -  Child living in the same house as the case&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Weeks</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Belem</city>
        <state>Pará</state>
        <zip>66 090 000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Justino MC, Linhares AC, Lanzieri TM, Miranda Y, Mascarenhas JD, Abreu E, Guerra SF, Oliveira AS, da Silva VB, Sanchez N, Meyer N, Shafi F, Ortega-Barria E, Soriano-Gabarró M, Colindres RE. Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil. Pediatr Infect Dis J. 2011 May;30(5):396-401. doi: 10.1097/INF.0b013e3182055cc2.</citation>
    <PMID>21150692</PMID>
  </reference>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>August 5, 2010</study_first_submitted>
  <study_first_submitted_qc>August 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2010</study_first_posted>
  <last_update_submitted>November 15, 2012</last_update_submitted>
  <last_update_submitted_qc>November 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

